VWR Corporation (NASDAQ:VWR) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

A number of other brokerages have also recently issued reports on VWR. Zacks Investment Research cut VWR Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. BidaskClub upgraded VWR Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. VWR Corporation has an average rating of “Hold” and an average target price of $31.67.

Shares of VWR Corporation (NASDAQ VWR) traded up $0.07 during trading on Tuesday, hitting $33.17. The stock had a trading volume of 610,151 shares, compared to its average volume of 1,060,000. VWR Corporation has a one year low of $24.42 and a one year high of $37.25. The company has a market cap of $4,360.00, a PE ratio of 18.19 and a beta of 1.17. The company has a current ratio of 1.19, a quick ratio of 0.76 and a debt-to-equity ratio of 1.13.

VWR Corporation (NASDAQ:VWR) last announced its quarterly earnings data on Tuesday, November 7th. The medical research company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.08. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the prior year, the business posted $0.44 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. analysts forecast that VWR Corporation will post 1.83 earnings per share for the current fiscal year.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/vwr-corporation-vwr-raised-to-buy-at-valuengine/1686518.html.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC raised its stake in VWR Corporation by 1,089.9% in the 3rd quarter. SG Americas Securities LLC now owns 191,283 shares of the medical research company’s stock valued at $6,333,000 after acquiring an additional 175,208 shares during the period. Crossmark Global Holdings Inc. bought a new stake in VWR Corporation in the 3rd quarter valued at $318,000. Aperio Group LLC raised its stake in VWR Corporation by 7.5% in the 3rd quarter. Aperio Group LLC now owns 53,329 shares of the medical research company’s stock valued at $1,766,000 after acquiring an additional 3,721 shares during the period. Colony Group LLC raised its stake in VWR Corporation by 6.5% in the 2nd quarter. Colony Group LLC now owns 144,191 shares of the medical research company’s stock valued at $4,760,000 after acquiring an additional 8,835 shares during the period. Finally, Amalgamated Bank raised its stake in VWR Corporation by 37.9% in the 2nd quarter. Amalgamated Bank now owns 15,445 shares of the medical research company’s stock valued at $510,000 after acquiring an additional 4,243 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

About VWR Corporation

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.

Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.